Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Pancreatic Neoplasms 2Lung Neoplasms 2Lethal Congenital Contracture Syndrome 2 2Head and Neck Neoplasms 2Fibromatosis, Gingival, 2 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor Cancers 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Kidney Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Bile Duct Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × seribantumab × Clear all
NCT02538627 2017-09-05

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Merrimack Pharmaceuticals

Phase 1 Terminated
5 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms

NCT01447225 2016-09-14

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

Merrimack Pharmaceuticals

Phase 1 Completed
43 enrolled 21 charts
Tumor-Agnostic

Neoplasms

NCT00734305 2016-09-01

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Merrimack Pharmaceuticals

Phase 1 Completed
44 enrolled 12 charts

Lethal Congenital Contracture Syndrome 2, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡